Read More

Cardinal Health Updated FY24 Adj EPS Guidance to High End of $6.75-$7.00 Vs $6.95 Est, Sees Execution of a New $250M Accelerated Share Repurchase Program in Q2, Reiterated its Long-Term Targets Reflecting 12%-14% Growth of Adj EPS

Fiscal 24 outlook update The company updated fiscal year 2024 non-GAAP diluted EPS guidance to the high end of its $6.75 to $7.00 range. This update is driven by anticipated

CAH

Read More

MaxCyte Announces Preliminary Q4 Revenue $15.5M-$15.7M Vs $10.74M Est.; FY23 Revenue $41.1M-$41.3M Vs $36.72M Est.; Total Cash, Cash Equivalents, And Investments As Of December 31, 2023 Is Expected To Be ~$210M

MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell

MXCT

Read More

Sarepta Therapeutics Reports Preliminary Q4 Net Product Revenue For ELEVIDYS Are Expected To Be ~$131.3M And $200.4M For FY23; Preliminary Total Net Product Revenue Is Expected To Total $1.145B For FY23

– Preliminary total net product revenue is expected to total $1.145 billion for full-year 2023– Preliminary ELEVIDYS net product revenue is expected to be $131.3 million for the fourth quarter and $200.4 million for

SRPT